The PPD clinical research business of Thermo Fisher Scientific Inc. has unveiled a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin in the US.

The new 72,500-square-foot building increases the site’s chemistry, manufacturing and control (CMC) analytical capabilities as part of its clinical development and laboratory services focused on improving health by helping customers deliver life-changing medicines.

According to Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific “We will continue to support and empower our customers as they continue to discover, develop and deliver new groundbreaking therapies. This $58 million investment to expand the site is a testament to our dedication in supporting Thermo Fisher’s Mission of making the world healthier, cleaner and safer.”

The GMP site offers high-quality analytical services for small molecules and biologics, including biopharmaceuticals, inhaled pharmaceuticals and device testing, cell and gene therapy, protein characterization and mass spectrometry analysis for all phases of drug development.

The latest addition to the GMP campus provides a multi-use and flexible biosafety level 2 laboratory that includes a purpose-built liquid chromatography-mass spectrometry and protein characterization space, two large molecular suites with access controlled pre- and post-amplification labs, and two large general-use labs. The expansion will add up to 350 scientists and laboratory support professionals to the almost 2,300 employees working across the research campus.